Online inquiry

IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7446MR)

This product GTTS-WQ7446MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ITGA2 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002203.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3673
UniProt ID P17301
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ7446MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2286MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ4723MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ4482MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-931699
GTTS-WQ10343MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ8251MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HLX10
GTTS-WQ275MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ5590MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ2098MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AIN457
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW